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that support either the 2001 recommendations that have changed
or the new or revised recommendations are cited in parentheses
at the end of each recommendation or comment. A list of
abbreviations is included in the Appendix. The reader is referred
to the full-text guideline posted on the World Wide Web sites of
the ACC, the AHA, and the SCAI for a more detailed explana-
tion of the changes discussed here. Please note that we have
changed the table of contents headings in the 2001 ACC/AHA
Guidelines for Percutaneous Coronary Intervention from roman
numerals to unique identifying numbers.
In preparing this update, the committee was guided by the
following principles:
1. Changes in recommendations and levels of evidence
were made because of the availability of data from new
randomized trials, the accumulation of new clinical
evidence, and/or the development of clinical consensus.
2. The committee is cognizant of the healthcare, logistic,
and financial implications of recent trials and factored
in these considerations in arriving at the class level of
certain recommendations.
3. All recommendations in the PCI guideline update have
been written in full sentences that express a complete
thought, such that a recommendation, even if separated
and presented apart from the rest of the document, will
still convey the full intent of the recommendation.
4. The committee wishes to re-emphasize that the recom-
mendations in the guideline apply to most patients but may
require modification by existing situations that only the
primary treating healthcare provider can evaluate properly.
5. The committee endeavored to maintain the consistency
of recommendations in this and other previously pub-
lished guidelines, primarily the ACC/AHA Guidelines
for the Management of Patients With ST-Elevation
Myocardial Infarction and the ACC/AHA 2002 Guide-
line Update for the Management of Patients With
Non–ST-Elevation Myocardial Infarction.
The classification of recommendations and levels of evi-
dence are expressed in the ACC/AHA format as follows:
Classification of Recommendations
Class I: Conditions for which there is evidence for and/or
general agreement that a given procedure or treatment is
beneficial, useful, and effective.
Class II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the usefulness/efficacy
of a procedure or treatment.
IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
IIb: Usefulness/efficacy is less well established by
evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treatment is not useful/
effective and in some cases may be harmful.
Level of Evidence
Level of Evidence A: Data derived from multiple random-
ized clinical trials or meta-analyses.
Level of Evidence B: Data derived from a single randomized
trial or nonrandomized studies.
Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
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2001 Recommendation 2005 New or Revised Recommendation Comments
3. Outcomes
3.2 Acute Outcome: Procedural Complications
Class I Class I
None All patients who have signs or symptoms suggestive of MI
during or after PCI and those with complicated procedures
should have CK-MB and troponin I or T measured after the
procedure. (Level of Evidence: B)
This recommendation appeared in the text of the 2001
revision for CK-MB only. Troponin I or T measurement has
been added, and it is now listed as a class I, level of
evidence B recommendation (1–10).
Class IIa Class IIa
None Routine measurement of cardiac biomarkers (CK-MB and/or
troponin I or T) in all patients undergoing PCI is reasonable 8
to 12 hours after the procedure. (Level of Evidence: C)
Routine measurement of CK-MB or troponin I or T is
added as a new class IIa, level of evidence C
recommendation. The committee did not think that
evidence regarding the clinical utility of routine
measurement of biomarkers in all patients was
strong enough to warrant a class I recommendation.
4. Institutional and Operator Competency
4.1 Quality Assurance
Class I Class I
None 1. An institution that performs PCI should establish an
ongoing mechanism for valid peer review of its quality and
outcomes. Review should be conducted both at the level of
the entire program and at the level of the individual
practitioner. Quality-assessment reviews should take risk
adjustment, statistical power, and national benchmark
statistics into consideration. Quality-assessment reviews
should include both tabulation of adverse event rates for
comparison with benchmark values and case review of
complicated procedures and some uncomplicated
procedures. (Level of Evidence: C)
Quality assurance is an important responsibility for all
institutions in which PCI is performed. Institutions must
monitor the PCI program with respect to process,
appropriateness, and outcomes and correct any
circumstances in which quality falls below accepted
norms. The quality assessment should be conducted at
the level of both the entire program and the individual
practitioner.
2. An institution that performs PCI should participate in a
recognized PCI data registry for the purpose of benchmarking
its outcomes against current national norms. (Level of
Evidence: C)
Participation in a recognized PCI registry for
benchmarking outcomes against current national norms
is an important part of the quality-improvement
process. The ACC–National Cardiovascular Data
Registry® or other databases may serve as a valuable
resource in this regard.
4.2 Operator and Institutional Volume
Class I Class I
PCI done by operators with
acceptable volume (greater than or
equal to 75) at high-volume centers
(greater than 400). (Level of
Evidence: B)
1. Elective PCI should be performed by operators with acceptable
annual volume (at least 75 procedures) at high-volume centers
(more than 400 procedures) with on-site cardiac surgery. (Level of
Evidence: B)
Wording has been added to clarify this statement and
emphasize that it relates to elective PCI performed at
centers with on-site cardiac surgery.
2. Elective PCI should be performed by operators and
institutions whose historical and current risk-adjusted
outcomes statistics are comparable to those reported in
contemporary national data registries. (Level of Evidence: C)
This recommendation was added to emphasize that
historical and current risk-adjusted outcomes for
operators and institutions are an essential part of the
quality-improvement process.
3. Primary PCI for STEMI should be performed by
experienced operators who perform more than 75 elective
PCI procedures per year and, ideally, at least 11 PCI
procedures for STEMI per year. Ideally, these procedures
should be performed in institutions that perform more than
400 elective PCIs per year and more than 36 primary PCI
procedures for STEMI per year. (Level of Evidence: B)
This recommendation is expanded based on data from the
New York State registry indicating that physicians
performing more than 10 primary PCI procedures per year
have lower mortality rates (11–13).
Class IIa Class IIa
1. PCI done by operators with
acceptable volume (75 or more) at
low-volume centers (200–400).
(Level of Evidence: C)
1. It is reasonable that operators with acceptable volume (at
least 75 PCI procedures per year) perform PCI at low-volume
centers (200 to 400 PCI procedures per year) with on-site
cardiac surgery. (Level of Evidence: B)
Wording has been changed to comply with current
recommended phrasing for class IIa
recommendation. The fact that this recommendation
applies to centers with on-site cardiac surgery is
emphasized. Level of evidence has been changed to
B based on accumulated published evidence (14).
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2001 Recommendation 2005 New or Revised Recommendation Comments
2. PCI done by low-volume operators
(fewer than 75) at high-volume centers
(more than 400). Note: Ideally
operators with an annual procedure
volume less than 75 should only work
at institutions with an activity level of
more than 600 procedures/year.*
(Level of Evidence: C)
*Operators who perform fewer than 75
procedures per year should develop a
defined mentoring relationship with a
highly experienced operator who has
an annual procedural volume of at
least 150 procedures per year.
2. It is reasonable that low-volume operators (fewer than 75
PCI procedures per year) perform PCI at high-volume centers
(more than 400 PCI procedures per year) with on-site cardiac
surgery. Ideally, operators with an annual procedure volume
less than 75 should only work at institutions with an activity
level of more than 600 procedures per year. Operators who
perform fewer than 75 procedures per year should develop a
defined mentoring relationship with a highly experienced
operator who has an annual procedural volume of at least 150
procedures per year. (Level of Evidence: B)
Wording has been changed to comply with current
recommended phasing. Level of evidence has been
changed to B based on accumulated published
evidence (15).
Class IIb Class IIb
None The benefit of primary PCI for STEMI patients eligible for
fibrinolysis when performed by an operator who performs
fewer than 75 procedures per year (or fewer than 11 PCIs for
STEMI per year) is not well established. (Level of Evidence: C)
This recommendation has been added to address the
issue of low-volume operators performing primary PCI.
It reflects the relative lack of evidence supporting a
benefit of primary PCI for low-volume operators.
Class III Class III
PCI done by low-volume operators
(fewer than 75) at low-volume
centers (200–400). Note: An
institution with a volume of fewer
than 200 procedures/year, unless
in a region that is underserved
because of geography, should
carefully consider whether it should
continue to offer service.* (Level of
Evidence: C)
*Operators who perform fewer than
75 procedures per year should
develop a defined mentoring
relationship with a highly
experienced operator who has an
annual procedural volume of at
least 150 procedures per year.
It is not recommended that elective PCI be performed by
low-volume operators (fewer than 75 procedures per year) at
low-volume centers (200 to 400) with or without on-site
cardiac surgery. An institution with a volume of fewer than
200 procedures per year, unless in a region that is
underserved because of geography, should carefully consider
whether it should continue to offer this service. (Level of
Evidence: B)
Wording has been changed to reflect current preferred
phrasing. Level of evidence changed to B on the basis
of published data indicating poorer outcomes at
low-volume centers (15).
4.3. Role of On-Site Cardiac Surgical Back-up
Class I Class I
1. Patients undergoing elective PCI in
facilities with on-site cardiac surgery.
(Level of Evidence: B)
1. Elective PCI should be performed by operators with
acceptable annual volume (at least 75 procedures per year) at
high-volume centers (more than 400 procedures annually) that
provide immediately available on-site emergency cardiac
surgical services. (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology and volume criteria; otherwise, no
significant changes.
2. Patients undergoing primary PCI in
facilities with on-site cardiac surgery.
(Level of Evidence: B)
2. Primary PCI for patients with STEMI should be performed in
facilities with on-site cardiac surgery. (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology and to be consistent with the ACC/AHA
Guidelines for the Management of Patients With
ST-Elevation Myocardial Infarction.
Class III Class III
Patients undergoing elective PCI in
facilities without on-site cardiac
surgery. (Level of Evidence: C)
Elective PCI should not be performed at institutions that do not
provide on-site cardiac surgery.* (Level of Evidence: C)
*Several centers have reported satisfactory results based on
careful case selection with well-defined arrangements for
immediate transfer to a surgical program (18–28). A small, but
real fraction of patients undergoing elective PCI will experience a
life-threatening complication that could be managed with the
immediate on-site availability of cardiac surgical support but
cannot be managed effectively by urgent transfer. Wennberg et al.
found higher mortality in the Medicare database for patients
undergoing elective PCI in institutions without onsite cardiac
surgery (29). These recommendations may be subject to revision
as clinical data and experience increase.
Phrasing has been changed to reflect current
terminology. As with many dynamic areas in
interventional cardiology, these recommendations may
be subject to revision as clinical data and experience
increase.
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Section 4.4 Primary PCI for STEMI Without On-Site Cardiac Surgery
Class IIb Class IIb
Patients undergoing primary PCI in
facilities without on-site cardiac surgery,
but with a proven plan for rapid access
(within 1 h) to a cardiac surgery
operating room in a nearby facility with
appropriate hemodynamic support
capability for transfer. The procedure
should be limited to patients with
ST-segment elevation MI or new LBBB
on ECG, and done in a timely fashion
(balloon inflation within 90 plus or minus
30 min of admission) by persons skilled
in the procedure (at least 75 PCIs/year)
and only at facilities performing a
minimum of 36 primary PCI procedures
per year. (Level of Evidence: B)
Primary PCI for patients with STEMI might be considered in hospitals
without on-site cardiac surgery, provided that appropriate planning for
program development has been accomplished, including appropriately
experienced physician operators (more than 75 total PCIs and, ideally,
at least 11 primary PCIs per year for STEMI), an experienced
catheterization team on a 24 hours per day, 7 days per week call
schedule, and a well-equipped catheterization laboratory with digital
imaging equipment, a full array of interventional equipment, and
intra-aortic balloon pump capability, and provided that there is a
proven plan for rapid transport to a cardiac surgery operating room in
a nearby hospital with appropriate hemodynamic support capability for
transfer. The procedure should be limited to patients with STEMI or
MI with new or presumably new LBBB on ECG and should be
performed in a timely fashion (goal of balloon inflation within 90
minutes of presentation) by persons skilled in the procedure (at least
75 PCIs per year) and at hospitals that perform a minimum of 36
primary PCI procedures per year. (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology. Recommendations have been added that
1) physicians perform at least 11 primary PCIs per year
for STEMI, 2) a 24 hours per day, 7 days per week call
schedule be maintained, and 3) the catheterization
laboratory be well equipped with digital imaging
equipment, a full array of interventional equipment, and
intra-aortic balloon pump capability. The intent is to
ensure optimal experience availability and capability to
perform primary PCI in patients with STEMI (16,17).
Class III Class III
Patients undergoing primary PCI in
facilities without on-site cardiac surgery
and without a proven plan for rapid
access (within 1 h) to a cardiac surgery
operating room in a nearby facility with
appropriate hemodynamic support
capability for transfer or when performed
by lower-skilled operators (fewer than 75
PCIs per year) in a facility performing
fewer than 36 primary PCI procedures
per year. (Level of Evidence: C)
Primary PCI should not be performed in hospitals without
on-site cardiac surgery and without a proven plan for rapid
transport to a cardiac surgery operating room in a nearby
hospital or without appropriate hemodynamic support capability
for transfer. (Level of Evidence: C)
Phrasing has been changed to reflect current
terminology and to place emphasis on need for
inter-institutional planning and support.
4.5 Elective PCI Without On-Site Surgery
Class III Class III
Patients undergoing elective PCI in
facilities without on-site cardiac
surgery. (Level of Evidence: C)
Elective PCI should not be performed at institutions that do not
provide on-site cardiac surgery. (Level of Evidence: C) *Several
centers have reported satisfactory results based on careful case
selection with well-defined arrangements for immediate transfer to a
surgical program (18–28). A small, but real fraction of patients
undergoing elective PCI will experience a life-threatening complication
that could be managed with the immediate on-site availability of
cardiac surgical support but cannot be managed effectively by urgent
transfer. Wennberg et al. found higher mortality in the Medicare
database for patients undergoing elective PCI in institutions without
onsite cardiac surgery (29). These recommendations may be subject
to revision as clinical data and experience increase.
Repeated from previous section for consistency.
Phrasing has been changed to reflect current
terminology.
5.1. Patients With Asymptomatic Ischemia or Canadian Cardiovascular Society (CCS) Class I or II Angina
Class I Class IIa
Patients who do not have treated
diabetes with asymptomatic ischemia or
mild angina with 1 or more significant
lesions in 1 or 2 coronary arteries
suitable for PCI with a high likelihood of
success and a low risk of morbidity and
mortality. The vessels to be dilated must
subtend a large area of viable
myocardium. (Level of Evidence: B)
1. PCI is reasonable in patients with asymptomatic ischemia or
CCS class I or II angina and with 1 or more significant lesions in
1 or 2 coronary arteries suitable for PCI with a high likelihood of
success and a low risk of morbidity and mortality. The vessels to
be dilated must subtend a moderate to large area of viable
myocardium or be associated with a moderate to severe degree
of ischemia on noninvasive testing. (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology. This recommendation and all of those that
follow in Section 5 have been reworded to be
consistent with the CCS classification system of angina.
This recommendation has been changed to class IIa to
reflect the published data and Writing Committee
consensus that not all patients in this clinical category
must have PCI performed (30,31).
Class IIa
1. The same clinical and anatomic
requirements for Class I, except the
myocardial area at risk is of moderate
size or the patient has treated
diabetes. (Level of Evidence: B)
This recommendation has been merged with other
class IIa recommendations of this section, and the
phrasing has been changed to reflect current
terminology.
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2001 Recommendation 2005 New or Revised Recommendation Comments
2. PCI is reasonable for patients with asymptomatic ischemia or
CCS class I or II angina, and recurrent stenosis after PCI with a
large area of viable myocardium or high-risk criteria on
noninvasive testing. (Level of Evidence: C)
This is a new recommendation dealing with the
management of recurrent stenosis after PCI among
patients with asymptomatic ischemia or class I or II
angina.
3. Use of PCI is reasonable in patients with asymptomatic ischemia
or CCS class I or II angina with significant left main CAD (greater
than 50% diameter stenosis) who are candidates for
revascularization but are not eligible for CABG. (Level of Evidence: B)
This recommendation for PCI among patients who are
eligible for CABG who have significant left main
disease has been added to reflect the favorable
results noted by several trials with PCI (32–35).
Class IIb
Patients with asymptomatic ischemia or
mild angina with greater than or equal to 3
coronary arteries suitable for PCI with a
high likelihood of success and a low risk of
morbidity and mortality. The vessels to be
dilated must subtend at least a moderate
area of viable myocardium. In the
physician’s judgment, there should be
evidence of myocardial ischemia by ECG
exercise testing, stress nuclear imaging,
stress echocardiography or ambulatory ECG
monitoring or intracoronary physiologic
measurements. (Level of Evidence: B)
This recommendation has been eliminated and
replaced by the following 2 recommendations. For
each, the phrasing has been constructed to reflect
current terminology.
Class IIb
1. The effectiveness of PCI for patients with asymptomatic
ischemia or CCS class I or II angina who have 2- or 3-vessel
disease with significant proximal LAD CAD who are otherwise
eligible for CABG with 1 arterial conduit and who have treated
diabetes or abnormal LV function is not well established.
(Level of Evidence: B)
Phrasing has been changed to reflect current
terminology. Among patients who are eligible, CABG
with 1 arterial conduit is generally preferred for
treatment of multivessel disease with significant
proximal LAD obstruction in patients with treated
diabetes and/or abnormal LV function (36).
2. PCI might be considered for patients with asymptomatic ischemia
or CCS class I or II angina with nonproximal LAD CAD that subtends
a moderate area of viable myocardium and demonstrates ischemia
on noninvasive testing. (Level of Evidence: C)
Phrasing has been changed to reflect current
terminology. PCI might be considered in this clinical
setting.
Class III Class III
Patients with asymptomatic ischemia or
mild angina who do not meet the
criteria as listed under Class I or Class
II and who have:
a. Only a small area of viable
myocardium at risk
b. No objective evidence of ischemia
c. Lesions that have a low likelihood
of successful dilatation
d. Mild symptoms that are unlikely
to be due to myocardial ischemia
e. Factors associated with increased
risk of morbidity or mortality
f. Left main disease
g. Insignificant disease less than
50% (Level of Evidence: C)
PCI is not recommended in patients with asymptomatic
ischemia or CCS class I or II angina who do not meet the
criteria as listed under the class II recommendations or who
have 1 or more of the following:
a. Only a small area of viable myocardium at risk (Level of
Evidence: C)
b. No objective evidence of ischemia (Level of Evidence: C)
c. Lesions that have a low likelihood of successful
dilatation (Level of Evidence: C)
d. Mild symptoms that are unlikely to be due to myocardial
ischemia (Level of Evidence: C)
e. Factors associated with increased risk of morbidity or
mortality (Level of Evidence: C)
f. Left main disease and eligibility for CABG (Level of
Evidence: C)
g. Insignificant disease (less than 50% coronary stenosis)
(Level of Evidence: C)
Phrasing has been changed to reflect current
terminology. Recommendation has been reworded to
be consistent with CCS classification system for
angina. Level of evidence has been added for each
subgroup.
5.2 Patients With CCS Class III Angina
Class I Class IIa
Patients with 1 or more significant lesions
in 1 or more coronary arteries suitable for
PCI with a high likelihood of success and
low risk of morbidity or mortality. The
vessel(s) to be dilated must subtend a
moderate or large area of viable
myocardium and have high risk. (Level of
Evidence: B)
1. It is reasonable that PCI be performed in patients with CCS
class III angina and single-vessel or multivessel CAD who are
undergoing medical therapy and who have 1 or more
significant lesions in 1 or more coronary arteries suitable for
PCI with a high likelihood of success and low risk of
morbidity or mortality. (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology. Recommendation has been reworded to be
consistent with CCS classification system for angina. The
recommendation class has been changed to IIa to reflect
published data and Writing Committee consensus.
Criteria regarding viable and high-risk myocardium have
been deleted from this recommendation (30, 31).
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Class IIa
Patients with focal saphenous vein
graft lesions or multiple stenoses
who are poor candidates for
reoperative surgery. (Level of
Evidence: C)
2. It is reasonable that PCI be performed in patients with CCS
class III angina with single-vessel or multivessel CAD who are
undergoing medical therapy with focal saphenous vein graft
lesions or multiple stenoses who are poor candidates for
reoperative surgery. (Level of Evidence: C)
Phrasing has been changed to reflect current
terminology.
3. Use of PCI is reasonable in patients with CCS class III
angina with significant left main CAD (greater than 50%
diameter stenosis) who are candidates for revascularization but
are not eligible for CABG. (Level of Evidence: B)
This recommendation for PCI among patients with
significant left main disease who are not eligible for
CABG has been added to reflect the favorable results
noted by several trials with PCI (32–35).
Class IIb Class IIb
Patient has 1 or more lesions to be
dilated with reduced likelihood of
success or the vessel(s) subtend a
less than moderate area of viable
myocardium. Patients with 2- or
3-vessel disease, with significant
proximal LAD CAD and treated
diabetes or abnormal LV function.
(Level of Evidence: B)
1. PCI may be considered in patients with CCS class III angina
with single-vessel or multivessel CAD who are undergoing
medical therapy and who have 1 or more lesions to be dilated
with a reduced likelihood of success. (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology. The 2001 recommendation has been split
into 2 separate recommendations.
2. PCI may be considered in patients with CCS class III angina
and no evidence of ischemia on noninvasive testing or who
are undergoing medical therapy and have 2- or 3-vessel CAD
with significant proximal LAD CAD and treated diabetes or
abnormal LV function. (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology. The use of noninvasive testing to evaluate
for evidence of ischemia has been added.
Class III Class III
Patient has no evidence of
myocardial injury or ischemia on
objective testing and has not had a
trial of medical therapy, or has
a. Only a small area of
myocardium at risk
b. All lesions or the culprit lesion
to be dilated with morphology with
a low likelihood of success
c. A high risk of procedure-related
morbidity or mortality. (Level of
Evidence: C)
PCI is not recommended for patients with CCS class III angina
with single-vessel or multivessel CAD, no evidence of
myocardial injury or ischemia on objective testing, and no trial
of medical therapy, or who have 1 of the following:
a. Only a small area of myocardium at risk (Level of
Evidence: C)
b. All lesions or the culprit lesion to be dilated with
morphology that conveys a low likelihood of success (Level
of Evidence: C)
c. A high risk of procedure-related morbidity or mortality
(Level of Evidence: C)
d. Insignificant disease (less than 50% coronary stenosis)
(Level of Evidence: C)
e. Significant left main CAD and candidacy for CABG (Level of
Evidence: C)
Phrasing has been changed to reflect current
terminology. Class III recommendations #2 and #3 from
the 2001 guidelines have been merged into this
recommendation.
2. Patients with insignificant
coronary stenosis (e.g., less than
50% diameter). (Level of Evidence:
C)
See above.
3. Patients with significant left main
CAD who are candidates for CABG.
(Level of Evidence: B)
See above.
5.3 Unstable Angina/Non–ST-Elevation Myocardial Infarction (UA/NSTEMI)
(Note: Some of these recommendations have been repeated from above because the sections for the 2005 guideline were revised slightly.)
Class I
An early invasive PCI strategy is indicated for patients with
UA/NSTEMI who have no serious comorbidity and who have
coronary lesions amenable to PCI. Patients must have any of
the following high-risk features:
a. Recurrent ischemia despite intensive anti-ischemic
therapy (Level of Evidence: A)
b. Elevated troponin level (Level of Evidence: A)
c. New ST-segment depression (Level of Evidence: A)
d. CHF symptoms or new or worsening MR (Level of
Evidence: A)
e. Depressed LV systolic function (Level of Evidence: A)
f. Hemodynamic instability (Level of Evidence: A)
g. Sustained ventricular tachycardia (Level of Evidence: A)
h. PCI within 6 months (Level of Evidence: A)
i. Prior CABG (Level of Evidence: A)
Added to maintain consistency with the ACC/AHA 2002
Guideline Update for the Management of Patients With
Unstable Angina and Non–ST-Segment Myocardial
Infarction (37).
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Class IIa Class IIa
1. Patients with focal saphenous vein
graft lesions or multiple stenoses
who are poor candidates for
reoperative surgery. (Level of
Evidence: C)
1. It is reasonable that PCI be performed in patients with
UA/NSTEMI and single-vessel or multivessel CAD who are
undergoing medical therapy with focal saphenous vein graft
lesions or multiple stenoses who are poor candidates for
reoperative surgery. (Level of Evidence: C)
Phrasing has been changed to reflect current
terminology.
2. In the absence of high-risk features associated with
UA/NSTEMI, it is reasonable to perform PCI in patients with
amenable lesions and no contraindication for PCI with either
an early invasive or early conservative strategy. See full-text
guidelines. (Level of Evidence: B)
Added in accordance with growing evidence regarding
PCI for patients with UA/NSTEMI (30, 37–39).
3. Use of PCI is reasonable in patients with UA/NSTEMI with
significant left main CAD (greater than 50% diameter stenosis)
who are candidates for revascularization but are not eligible for
CABG. (Level of Evidence: B)
Added in accordance with growing evidence regarding
PCI for patients with UA/NSTEMI (32–35, 40–43).
Class IIb
1. In the absence of high-risk features associated with
UA/NSTEMI, PCI may be considered in patients with
single-vessel or multivessel CAD who are undergoing medical
therapy and who have 1 or more lesions to be dilated with
reduced likelihood of success. (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology. Original recommendation replaced by 2
separate recommendations as noted here and in the
following recommendations.
2. PCI may be considered in patients with UA/NSTEMI who are
undergoing medical therapy who have 2- or 3-vessel disease,
significant proximal LAD CAD, and treated diabetes or
abnormal LV function. (Level of Evidence: B)
See above.
2. All patients after a non–Q-wave
MI. (Level of Evidence: C)
This recommendation was removed because it is now
covered by the revised recommendations from the
ACC/AHA 2002 Guideline Update for the Management of
Patients With Unstable Angina and Non–ST-Segment
Myocardial Infarction.
Class III Class III
1. Patient has no evidence of
myocardial injury or ischemia on
objective testing and has not had a
trial of medical therapy, or has
a. Only a small area of myocardium at
risk
b. All lesions or the culprit lesion to be
dilated with morphology with a low
likelihood of success
c. A high risk of procedure-related
morbidity or mortality. (Level of
Evidence: C)
1. In the absence of high-risk features associated with
UA/NSTEMI, PCI is not recommended for patients with
UA/NSTEMI with single-vessel or multivessel CAD and no trial
of medical therapy, or who have 1 or more of the following
a. Only a small area of myocardium at risk (Level of
Evidence: C)
b. All lesions or the culprit lesion to be dilated with
morphology that conveys a low likelihood of success (Level
of Evidence: C)
c. A high risk of procedure-related morbidity or mortality
(Level of Evidence: C)
d. Insignificant disease (less than 50% coronary stenosis)
(Level of Evidence: C)
e. Significant left main CAD and candidacy for CABG (Level
of Evidence: B)
Phrasing has been changed to reflect current
terminology and level of evidence for each subgroup.
Class III recommendations #2 and #3 from the 2001
guidelines have been merged into this recommendation.
2. Patients with insignificant
coronary stenosis (e.g., less than
50% diameter). (Level of Evidence:
C)
See above.
3. Patients with significant left main
CAD who are candidates for CABG.
(Level of Evidence: B)
See above.
5.4. Patients With STEMI
The phrasing has been changed to reflect current terminology as needed for all recommendations in this section and to be consistent with the ACC/AHA
Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction.
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5.4.1. General and Specific Considerations
Class I Class I
1. As an alternative to thrombolytic
therapy in patients with AMI and
ST-segment elevation or new or
General considerations:
1. If immediately available, primary PCI should be performed in
patients with STEMI (including true posterior MI) or MI with
Phrasing has been changed to reflect current
terminology to be consistent with the ACC/AHA
Guidelines for the Management of Patients With
presumed new left bundle-branch
block who can undergo angioplasty
of the infarct artery less than or
equal to 12 h from the onset of
ischemic symptoms or more than 12
h if symptoms persist, if performed
in a timely fashion* by individuals
skilled in the procedure† and
supported by experienced personnel
in an appropriate laboratory
environment.‡ (Level of Evidence: A)
*Performance standard: balloon
inflation within 90 plus or minus 30
min of hospital admission.
†Individuals who perform 75 or more
PCI procedures per year.
‡Centers that perform more than
200 PCI procedures per year and
have cardiac surgical capability.
new or presumably new LBBB who can undergo PCI of the
infarct artery within 12 hours of symptom onset, if performed
in a timely fashion (balloon inflation goal within 90 minutes of
presentation) by persons skilled in the procedure (individuals
who perform more than 75 PCI procedures per year, ideally at
least 11 PCIs per year for STEMI). The procedure should be
supported by experienced personnel in an appropriate
laboratory environment (one that performs more than 200 PCI
procedures per year, of which at least 36 are primary PCI for
STEMI, and that has cardiac surgery capability). (Level of
Evidence: A) Primary PCI should be performed as quickly as
possible, with a goal of a medical contact–to-balloon or
door-to-balloon time within 90 minutes. (Level of Evidence: B)
ST-Elevation Myocardial Infarction. This revised
recommendation reflects the evidence from several
trials and a meta-analysis of 23 trials comparing PCI
with fibrinolysis that confirm the advantage of PCI. The
conditions under which PCI must be performed to
optimize this advantage are included in the
recommendation (11–13,44–47).
2. In patients who are within 36 h of
an acute ST elevation/Q-wave or new
left bundle-branch block MI who
develop cardiogenic shock, are less
than 75 years of age, and
revascularization can be performed
within 18 h of the onset of shock by
individuals skilled in the procedure†
and supported by experienced
personnel in an appropriate laboratory
environment.‡ (Level of Evidence: A)
†Individuals who perform 75 or more
PCI procedures per year.
‡Centers that perform more than 200
PCI procedures per year and have
cardiac surgical capability (193, 194).
Specific considerations:
2. Primary PCI should be performed for patients less than 75
years old with ST elevation or presumably new LBBB who
develop shock within 36 hours of MI and are suitable for
revascularization that can be performed within 18 hours of
shock, unless further support is futile because of the patient’s
wishes or contraindications/unsuitability for further invasive
care. (Level of Evidence: A)
Phrasing has been changed to reflect current
terminology. The changes from the ACC/AHA Guidelines
for the Management of Patients With ST-Elevation
Myocardial Infarction have been included in this
recommendation (48–53).
3. Primary PCI should be performed in patients with severe HF
and/or pulmonary edema (Killip class 3) and onset of symptoms
within 12 hours. The medical contact–to-balloon or
door-to-balloon time should be as short as possible (i.e., goal
within 90 minutes). (Level of Evidence: B)
The changes from the ACC/AHA Guidelines for the
Management of Patients With ST-Elevation Myocardial
Infarction are included in this new recommendation,
which emphasizes the benefits of PCI for patients with
severe CHF and onset of symptoms within 12 hours
(54–56).
Class IIa
1. Primary PCI is reasonable for selected patients 75 years or
older with ST elevation or LBBB or who develop shock within
36 hours of MI and are suitable for revascularization that can
be performed within 18 hours of shock. Patients with good
prior functional status who are suitable for revascularization
and agree to invasive care may be selected for such an
invasive strategy. (Level of Evidence: B)
This recommendation, which addresses the benefit of
PCI in patients at least 75 years of age with shock, is
included from the ACC/AHA Guidelines for the
Management of Patients With ST-Elevation Myocardial
Infarction with phrasing to reflect current terminology
(48–53).
2. It is reasonable to perform primary PCI for patients with onset
of symptoms within the prior 12 to 24 hours and 1 or more of the
following:
a. Severe HF (Level of Evidence: C)
b. Hemodynamic or electrical instability (Level of Evidence: C)
c. Evidence of persistent ischemia (Level of Evidence: C)
This new recommendation provides guidance for use of
primary PCI within 12 to 24 hours of symptom onset in
certain patient subsets. Phrasing has been changed to reflect
current terminology and to be consistent with the ACC/AHA
Guidelines for the Management of Patients With ST-Elevation
Myocardial Infarction.
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Class III Class III
1. Elective PCI of a
non–infarct-related artery at the time
of acute MI. (Level of Evidence: C)
1. Elective PCI should not be performed in a
non–infarct-related artery at the time of primary PCI of the
infarct-related artery in patients without hemodynamic
compromise. (Level of Evidence: C)
Phrasing has been changed to reflect current
terminology. Important phrasing has been added to
address the issue of PCI of the non–infarct-related
coronary artery at the time of primary PCI.
2. In patients with acute MI who:
a. have received fibrinolytic
therapy within 12 h and have no
symptoms of myocardial ischemia
b. are eligible for thrombolytic therapy
and are undergoing primary
angioplasty by an inexperienced
operator (Individual who performs
fewer than 75 PCI procedures per
year)
c. are beyond 12 h after onset of
symptoms and have no evidence of
myocardial ischemia. (Level of
Evidence: C)
2. Primary PCI should not be performed in asymptomatic
patients more than 12 hours after onset of STEMI who are
hemodynamically and electrically stable. (Level of Evidence: C)
Class IIb
1. The benefit of primary PCI for STEMI patients eligible for
fibrinolysis when performed by an operator who performs
fewer than 75 PCI procedures per year (or fewer than 11 PCIs
for STEMI per year) is not well established. (Level of Evidence:
C)
Phrasing has been changed to reflect current
terminology. Recommendation has been divided to
emphasize specific points. The class IIb
recommendation was upgraded in the ACC/AHA
Guidelines for the Management of Patients With
ST-Elevation Myocardial Infarction and approved by the
PCI Writing Committee.
5.4.2. PCI in Fibrinolytic-Ineligible Patients
Class IIa Class I
As a reperfusion strategy in
candidates who have a
contraindication to thrombolytic
therapy. (Level of Evidence: C)
Primary PCI should be performed in fibrinolytic-ineligible
patients who present with STEMI within 12 hours of symptom
onset. (Level of Evidence: C)
Revised recommendation reflects the committee’s opinion that
primary PCI should be a class I recommendation for
fibrinolytic-ineligible patients within 12 hours of symptom
onset. Phrasing has been changed to reflect current
terminology and to be consistent with the ACC/AHA Guidelines
for the Management of Patients With ST-Elevation Myocardial
Infarction.
Class IIa
It is reasonable to perform primary PCI for fibrinolytic-ineligible
patients with onset of symptoms within the prior 12 to 24
hours and 1 or more of the following:
a. Severe HF (Level of Evidence: C)
b. Hemodynamic or electrical instability (Level of Evidence:
C)
c. Evidence of persistent ischemia (Level of Evidence: C)
New recommendation from the ACC/AHA Guidelines for
the Management of Patients With ST-Elevation
Myocardial Infarction that addresses conditions under
which primary PCI is reasonable for fibrinolytic-ineligible
patients with onset of symptoms within the prior 12 to
24 hours.
5.4.3. Facilitated PCI
Class IIb Class IIb
None Facilitated PCI might be performed as a reperfusion strategy in
higher-risk patients when PCI is not immediately available and
bleeding risk is low. (Level of Evidence: B)
New recommendation from the ACC/AHA Guidelines for
the Management of Patients With ST-Elevation
Myocardial Infarction addressing conditions for which
facilitated PCI might be considered. Important
randomized trials are under way, and more data are
needed regarding outcomes resulting from this
treatment strategy (57–63).
5.4.4. PCI After Failed Fibrinolysis (Rescue PCI)
Class I Class I
None 1. Rescue PCI should be performed in patients less than 75
years old with ST elevation or LBBB who develop shock within
36 hours of MI and are suitable for revascularization that can
be performed within 18 hours of shock, unless further support
is futile because of the patient’s wishes or
contraindications/unsuitability for further invasive care. (Level
of Evidence: B)
See above (49,51).
2. Rescue PCI should be performed in patients with severe HF
and/or pulmonary edema (Killip class 3) and onset of
symptoms within 12 hours. (Level of Evidence: B)
See above (54–56).
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Class IIa Class IIa
None 1. Rescue PCI is reasonable for selected patients 75 years or
older with ST elevation or LBBB or who develop shock within
36 hours of MI and are suitable for revascularization that can
See above (49).
be performed within 18 hours of shock. Patients with good
prior functional status who are suitable for revascularization
and agree to invasive care may be selected for such an
invasive strategy. (Level of Evidence: B)
2. It is reasonable to perform rescue PCI for patients with 1 or
more of the following:
a. Hemodynamic or electrical instability (Level of Evidence:
C)
b. Evidence of persistent ischemia. (Level of Evidence: C)
Phrasing has been changed to reflect current
terminology.
Class IIb
Recurrent angina without objective
evidence of ischemia/infarction.
(Level of Evidence: C)
Deleted. Recurrent angina is not applicable to rescue
angioplasty. Recurrent symptoms are discussed
elsewhere.
Class III Class III
Routine PTCA within 48 h following
failed thrombolysis. (Level of
Evidence: B)
Rescue PCI in the absence of 1 or more of the above class I
or IIa indications is not recommended. (Level of Evidence: C)
Evidence obtained from studies of PTCA during the
fibrinolytic era before the use of stents failed to show a
benefit for reperfusion under these conditions. Current
trials are under way to investigate the outcome of PCI
with stent placement among patients with occluded
arteries days after presentation with STEMI.
5.4.5. PCI After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion
Class I Class I
1. Objective evidence for recurrent
infarction or ischemia (rescue PCI).
(Level of Evidence: B)
1. In patients whose anatomy is suitable, PCI should be
performed when there is objective evidence of recurrent MI.
(Level of Evidence: C)
Phrasing has been changed to reflect current
terminology. Revised to a level of evidence C.
2. Spontaneous or provocable
myocardial ischemia during recovery
from infarction. (Level of Evidence:
C)
2. In patients whose anatomy is suitable, PCI should be
performed for moderate or severe spontaneous or provocable
myocardial ischemia during recovery from STEMI. (Level of
Evidence: B)
Phrasing has been changed to reflect current
terminology. Level of evidence revised on the basis of
review by the Writing Committee (64).
3. Persistent hemodynamic
instability. (Level of Evidence: C)
3. In patients whose anatomy is suitable, PCI should be
performed for cardiogenic shock or hemodynamic instability.
See also Section 5.4.6 of the full-text guidelines. (Level of
Evidence: B)
Phrasing has been changed to reflect current terminology.
Level of evidence was revised on the basis of review by
the Writing Committee, and cardiogenic shock has been
added (cardiogenic shock is discussed in Section 5.4.6
and is a class I, level of evidence A recommendation for
patients younger than 75 years old and a class IIa, level of
evidence B recommendation for those aged 75 years and
older) (49).
Class IIa Class IIa
Patients with LV ejection fraction less
than or equal to 0.4, CHF, or serious
ventricular arrhythmias. (Level of
Evidence: C)
1. It is reasonable to perform routine PCI in patients with LV
ejection fraction less than or equal to 0.40, CHF, or serious
ventricular arrhythmias. (Level of Evidence: C)
Phrasing has been changed to reflect current
terminology.
Class IIb
1. Coronary angiography and
angioplasty for an occluded
infarct-related artery in an otherwise
stable patient to revascularize that
artery (open artery hypothesis).
(Level of Evidence: C)
Recommendation deleted. Important trials are under
way to provide evidence regarding outcomes associated
with or resulting from this therapy.
2. Angioplasty of the infarct-related
artery stenosis within hours to days
(48 h) following successful
thrombolytic therapy in asymptomatic
patients without clinical and/or
inducible evidence of ischemia. (Level
of Evidence: B)
This recommendation has been merged into the
upgraded class IIb recommendation for PCI after
fibrinolytic therapy below.
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Class IIa
3. Clinical HF during the acute episode,
but subsequent demonstration of
preserved LV function (LV ejection
fraction greater than 0.4). (Level of
Evidence: C)
2. It is reasonable to perform PCI when there is documented
clinical heart failure during the acute episode, even though
subsequent evaluation shows preserved LV function (LV ejection
fraction greater than 0.40). (Level of Evidence: C)
Phrasing has been changed to reflect current
terminology. Recommendation was upgraded to class
IIa by the Writing Committee.
Class III Class III
1. PCI of the infarct-related artery
within 48 to 72 h after thrombolytic
therapy without evidence of
spontaneous or provocable ischemia.
(Level of Evidence: C)
This recommendation has been upgraded and merged
into the IIb recommendation for PCI after fibrinolytic
therapy below.
Class IIb
2. Routine PCI of the infarct-artery
stenosis immediately after
thrombolytic therapy. (Level of
Evidence: A)
1. PCI might be considered as part of an invasive strategy after
fibrinolytic therapy. (Level of Evidence: C)
This recommendation has been upgraded to class IIb to
reflect a possible benefit from improved technology. The
Committee recognizes the potential benefit of this therapy
but believes more data are needed to define outcomes of
PCI after fibrinolytic therapy in the current era of improved
antiplatelet, anticoagulant, and drug-eluting stent therapies.
5.4.6. PCI for Cardiogenic Shock
Class I Class I
None Primary PCI is recommended for patients less than 75 years old with ST
elevation or LBBB who develop shock within 36 hours of MI and are
suitable for revascularization that can be performed within 18 hours of
shock, unless further support is futile because of the patient’s wishes or
contraindications/unsuitability for further invasive care. (Level of
Evidence: A)
Phrasing has been changed to reflect current
terminology and the ACC/AHA Guidelines for the
Management of Patients With ST-Elevation Myocardial
Infarction (48–53).
Class IIa Class IIa
Cardiogenic shock or hemodynamic
instability. (Level of Evidence: B)
Primary PCI is reasonable for selected patients 75 years or older
with ST elevation or LBBB who develop shock within 36 hours of
MI and are suitable for revascularization that can be performed
within 18 hours of shock. Patients with good prior functional
status who are suitable for revascularization and agree to
invasive care may be selected for such an invasive strategy.
(Level of Evidence: B)
Phrasing has been changed to reflect current
technology and modified to be consistent with the
ACC/AHA Guidelines for the Management of Patients
With ST-Elevation Myocardial Infarction (48–53).
5.5. Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery
Class I Class I
Patients with early ischemia (usually
within 30 days) after CABG (194).
(Level of Evidence: B)
1. When technically feasible, PCI should be performed in patients
with early ischemia (usually within 30 days) after CABG. (Level of
Evidence: B)
Phrasing has been changed to reflect current
terminology.
2. It is recommended that distal embolic protection devices be
used when technically feasible in patients undergoing PCI to
saphenous vein grafts. (Level of Evidence: B)
New recommendation is based on several studies
demonstrating efficacy of distal embolic protection
devices in PCI to saphenous vein grafts (65,66).
Class IIa Class IIa
1. Patients with ischemia occurring 1 to
3 years postoperatively and preserved LV
function with discrete lesions in graft
conduits. (Level of Evidence: B)
1. PCI is reasonable in patients with ischemia that occurs 1 to 3
years after CABG and who have preserved LV function with
discrete lesions in graft conduits. (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology.
2. Disabling angina secondary to
new disease in a native coronary
circulation. (If angina is not typical,
the objective evidence of ischemia
should be obtained.) (Level of
Evidence: B)
2. PCI is reasonable in patients with disabling angina secondary
to new disease in a native coronary circulation after CABG. (If
angina is not typical, objective evidence of ischemia should be
obtained.) (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology.
3. Patients with diseased vein grafts
more than 3 years following CABG.
(Level of Evidence: B)
3. PCI is reasonable in patients with diseased vein grafts more
than 3 years after CABG. (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology.
4. PCI is reasonable when technically feasible in patients with a
patent left internal mammary artery graft who have clinically
significant obstructions in other vessels. (Level of Evidence: C)
This new recommendation addresses the feasibility of
PCI to native circulation in the presence of a patent
left internal mammary artery graft.
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Class III Class III
1. PCI to chronic total vein graft
occlusions. (Level of Evidence: B)
1. PCI is not recommended in patients with prior CABG for
chronic total vein graft occlusions. (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology.
2. Patients with multivessel disease,
failure or multiple SVGs, and
impaired LV function. (Level of
Evidence: B)
2. PCI is not recommended in patients who have multiple target lesions
with prior CABG and who have multivessel disease, failure of multiple
SVGs, and impaired LV function unless repeat CABG poses excessive
risk due to severe comorbid conditions. (Level of Evidence: B)
Phrasing has been changed to reflect current
technology, and considerations regarding risk of
repeat CABG have been added (36).
5.6.1. Intravascular Ultrasound Imaging (IVUS)
Class IIa Class IIa
1. Assessment of the adequacy of
deployment of coronary stents,
including the extent of stent
apposition and determination of the
minimum luminal diameter within the
stent. (Level of Evidence: B)
2. Determination of the mechanism
of stent restenosis (inadequate
expansion vs. neointimal
proliferation) and to enable selection
of appropriate therapy (plaque
ablation vs. repeat balloon
expansion). (Level of Evidence: B)
3. Evaluation of coronary obstruction
at a location difficult to image by
angiography in a patient with a
suspected flow-limiting stenosis.
(Level of Evidence: C)
1. IVUS is reasonable for the following:
a. Assessment of the adequacy of deployment of coronary
stents, including the extent of stent apposition and
determination of the minimum luminal diameter within the
stent. (Level of Evidence: B)
b. Determination of the mechanism of stent restenosis
(inadequate expansion versus neointimal proliferation) and to
enable selection of appropriate therapy (vascular
brachytherapy versus repeat balloon expansion). (Level of
Evidence: B)
c. Evaluation of coronary obstruction at a location difficult to
image by angiography in a patient with a suspected
flow-limiting stenosis. (Level of Evidence: C)
d. Assessment of a suboptimal angiographic result after PCI.
(Level of Evidence: C)
e. Establishment of the presence and distribution of coronary
calcium in patients for whom adjunctive rotational
atherectomy is contemplated. (Level of Evidence: C)
f. Determination of plaque location and circumferential distribution for
guidance of directional coronary atherectomy. (Level of Evidence: B)
Phrasing has been changed to reflect current
terminology. The previous class IIa recommendations
for IVUS have been listed together in the
recommendation rather than separately, with the
exception that the Writing Committee has changed
the recommendation to evaluate coronary disease
after transplantation to class IIb.
4. Assessment of a suboptimal
angiographic result following PCI.
(Level of Evidence: C)
5. Diagnosis and management of
coronary disease following cardiac
transplantation. (Level of Evidence: C)
6. Establish presence and distribution
of coronary calcium in patients for
whom adjunctive rotational
atherectomy is contemplated. (Level of
Evidence: C)
7. Determination of plaque location
and circumferential distribution for
guidance of directional coronary
atherectomy. (Level of Evidence: B)
Class IIb Class IIb
1. Determine extent of
atherosclerosis in patients with
characteristic anginal symptoms and
a positive functional study with no
focal stenoses or mild CAD on
angiography. (Level of Evidence: C)
2. Preinterventional assessment of
lesional characteristics and vessel
dimensions as a means to select an
optimal revascularization device. (Level of
Evidence: C)
IVUS may be considered for the following:
a. Determination of the extent of atherosclerosis in patients
with characteristic anginal symptoms and a positive functional
study with no focal stenoses or mild CAD on angiography.
(Level of Evidence: C)
b. Preinterventional assessment of lesional characteristics and
vessel dimensions as a means to select an optimal
revascularization device. (Level of Evidence: C)
c. Diagnosis of coronary disease after cardiac transplantation.
(Level of Evidence: C)
Phrasing has been changed to reflect current
terminology. The previous class IIb recommendations
for IVUS have been listed together in this
recommendation rather than separately. The use of
IVUS to evaluate coronary disease in transplant
patients is now a class IIb recommendation.
Class III Class III
When angiographic diagnosis is clear
and no interventional treatment is
planned. (Level of Evidence: C)
IVUS is not recommended when the angiographic diagnosis is
clear and no interventional treatment is planned. (Level of
Evidence: C)
Phrasing has been changed to reflect current
terminology.
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5.6.2. Coronary Artery Pressure and Flow: Use of Fractional Flow Reserve and Coronary Vasodilatory Reserve
Class IIa Class IIa
Assessment of the physiological effects
of intermediate coronary stenoses (30 to
70% luminal narrowing) in patients with
anginal symptoms. Coronary pressure or
Doppler velocimetry may also be useful
as an alternative to performing
noninvasive functional testing (e.g., when
the functional study is absent or
ambiguous) to determine whether an
intervention is warranted. (Level of
Evidence: B)
It is reasonable to use intracoronary physiologic
measurements (Doppler ultrasound, fractional flow reserve)
in the assessment of the effects of intermediate coronary
stenoses (30% to 70% luminal narrowing) in patients with
anginal symptoms. Coronary pressure or Doppler
velocimetry may also be useful as an alternative to
performing noninvasive functional testing (e.g., when the
functional study is absent or ambiguous) to determine
whether an intervention is warranted. (Level of Evidence:
B)
Phrasing has been changed to reflect current terminology.
Class IIb Class IIb
1. Evaluation of the success of
percutaneous coronary
revascularization in restoring flow
reserve and to predict the risk of
restenosis. (Level of Evidence: C)
1. Intracoronary physiologic measurements may be
considered for the evaluation of the success of PCI in
restoring flow reserve and to predict the risk of restenosis.
(Level of Evidence: C)
Phrasing has been changed to reflect current terminology.
2. Evaluation of patients with anginal
symptoms without an apparent
angiographic culprit lesion. (Level of
Evidence: C)
2. Intracoronary physiologic measurements may be
considered for the evaluation of patients with anginal
symptoms without an apparent angiographic culprit lesion.
(Level of Evidence: C)
Phrasing has been changed to reflect current terminology.
Class III Class III
Routine assessment of the severity of
angiographic disease in patients with a
positive, unequivocal noninvasive
functional study. (Level of Evidence: C)
Routine assessment with intracoronary physiologic measurements
such as Doppler ultrasound or fractional flow reserve to assess
the severity of angiographic disease in patients with a positive,
unequivocal noninvasive functional study is not recommended.
(Level of Evidence: C)
Phrasing has been changed to reflect current terminology.
6. Management of Patients Undergoing PCI
6.1. Evolution of Technologies
6.1.1. Acute Results
Class I
It is recommended that distal embolic protection devices
be used when technically feasible in patients undergoing
PCI to saphenous vein grafts. (Level of Evidence: B)
Published clinical trials using distal embolic protection
devices confirm their benefit in improving cardiovascular
outcomes among patients undergoing PCI to saphenous
vein grafts (65,66).
6.2. Antiplatelet and Antithrombotic Adjunctive Therapies for PCI
6.2.1. Oral Antiplatelet Therapy
Class I
The recommendations in this section
appeared in table format in the 2001
guideline (see 2001 Table). The phrasing
has been changed to reflect current
terminology and to be consistent with
new evidence and/or recommendations
in the ACC/AHA Guidelines for the
Management of Patients With
ST-Elevation Myocardial Infarction and
the ACC/AHA 2002 Guideline Update for
Patients With Unstable
Angina/Non–ST-Elevation Myocardial
Infarction.
1. Patients already taking daily chronic aspirin therapy
should take 75 to 325 mg of aspirin before the PCI
procedure is performed. (Level of Evidence: A)
A daily dose of 75 mg of aspirin has been shown to result
in improved cardiovascular outcomes similar to daily doses
of 325 mg but with fewer bleeding complications (67–69).
2. Patients not already taking daily chronic aspirin therapy
should be given 300 to 325 mg of aspirin at least 2 hours
and preferably 24 hours before the PCI procedure is
performed. (Level of Evidence: C)
Higher doses of aspirin are recommended for patients not
already taking aspirin therapy immediately before PCI
procedures.
3. After the PCI procedure, in patients with neither aspirin
resistance, allergy, nor increased risk of bleeding, aspirin
325 mg daily should be given for at least 1 month after
bare-metal stent implantation, 3 months after
sirolimus-eluting stent implantation, and 6 months after
paclitaxel-eluting stent implantation, after which daily
chronic aspirin use should be continued indefinitely at a
dose of 75 to 162 mg. (Level of Evidence: B)
The doses and duration of aspirin therapy recommended herein
are derived from those used for US Food and Drug Administration
approval of the specific stent types noted in the recommendation.
Daily chronic aspirin therapy is based on recommendations in the
ACC/AHA Guidelines for the Management of Patients With
ST-Elevation Myocardial Infarction and evidence indicating that
aspirin therapy in dosages as low as 75 mg per day yields
outcomes similar to those achieved with 325 mg per day but with
fewer side effects (67,69–71).
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4. A loading dose of clopidogrel should be administered before PCI is
performed. (Level of Evidence: A) An oral loading dose of 300 mg,
administered at least 6 hours before the procedure, has the best
established evidence of efficacy. (Level of Evidence: B)
Clopidogrel is an important adjunctive therapy for
patients undergoing PCI with stent placement. The
best evidence of efficacy exists for 300 mg given
at least 6 hours before PCI is performed
(68,69,72).
5. In patients who have undergone PCI, clopidogrel 75 mg daily should
be given for at least 1 month after bare-metal stent implantation (unless
the patient is at increased risk for bleeding; then it should be given for
a minimum of 2 weeks), 3 months after sirolimus stent implantation,
and 6 months after paclitaxel stent implantation, and ideally up to 12
months in patients who are not at high risk of bleeding. (Level of
Evidence: B)
Clopidogrel therapy in the dosage of 75 mg daily
should be given after stent placement to all
patients. The duration of therapy varies for each
stent and is based on data from clinical trials used
for US Food and Drug Administration approval of
that stent (67,69–71).
Class IIa
1. If clopidogrel is given at the time of procedure,
supplementation with GP IIb/IIIa receptor antagonists can be
beneficial to facilitate earlier platelet inhibition than with
clopidogrel alone. (Level of Evidence: B)
When clopidogrel is given at the time of a PCI
procedure, supplementation with glycoprotein
IIb/IIIa receptor antagonists can be beneficial,
especially among high-risk patients (73,74).
2. For patients with an absolute contraindication to aspirin, it is
reasonable to give a 300-mg loading dose of clopidogrel, administered
at least 6 hours before PCI, and/or GP IIb/IIIa antagonists, administered
at the time of PCI. (Level of Evidence: C)
A significant number of patients will have
resistance to aspirin. The strongest evidence
for clopidogrel benefit exists for doses of 300
mg given at least 6 hours before the
procedure.
3. When a loading dose of clopidogrel is administered, a regimen of
greater than 300 mg is reasonable to achieve higher levels of
antiplatelet activity more rapidly, but the efficacy and safety compared
with a 300-mg loading dose are less established. (Level of Evidence: C)
Many patients receive clopidogrel therapy at the
time of PCI in dosages greater than 600 mg.
Although more pronounced inhibition of platelet
function has been demonstrated for doses of
clopidogrel greater than 300 mg, the safety of
these higher doses and their benefits on clinical
outcome are not fully established.
4. It is reasonable that patients undergoing brachytherapy be given daily
clopidogrel 75 mg indefinitely and daily aspirin 75 to 325 mg indefinitely
unless there is significant risk for bleeding. (Level of Evidence: C)
Subacute or later thrombosis has been
observed in patients undergoing
brachytherapy, and for this reason long-term
antiplatelet therapy is recommended.
Class IIb
In patients in whom subacute thrombosis may be catastrophic or
lethal (unprotected left main, bifurcating left main, or last patent
coronary vessel), platelet aggregation studies may be considered
and the dose of clopidogrel increased to 150 mg per day if less
than 50% inhibition of platelet aggregation is demonstrated.
(Level of Evidence: C)
Clopidogrel resistance is a significant problem, and
owing to its contribution to catastrophic clinical
outcomes, the Writing Committee recommends
studies be performed with increases in clopidogrel
dose being recommended for use in those with
higher-risk lesions.
6.2.2 Glycoprotein IIb/IIIa Inhibitors
Class I
The recommendations in this section appeared in
table format in the 2001 guideline (see 2001
Table). The phrasing has been changed to reflect
current terminology and to be consistent with
new evidence and/or recommendations in the
ACC/AHA Guidelines for the Management of
Patients With ST-Elevation Myocardial Infarction
and the ACC/AHA 2002 Guideline Update for the
Management of Patients With Unstable Angina/
Non–ST-Elevation Myocardial Infarction.
In patients with UA/NSTEMI undergoing PCI without clopidogrel
administration, a GP IIb/IIIa inhibitor (abciximab, eptifibatide, or
tirofiban) should be administered. (Level of Evidence: A)§
§It is acceptable to administer the GP IIb/IIIa inhibitor before
performance of the diagnostic angiogram (“upstream treatment”)
or just before PCI (“in-lab treatment”).
This recommendation and phrasing are compatible
with the ACC/AHA 2002 Guideline Update for the
Management of Patients With Unstable Angina and
Non–ST-Segment Myocardial Infarction and current
evidence from randomized clinical trials. The
benefits of GP IIb/IIIa inhibition are especially
efficacious when clopidogrel is not given (37).
Class IIa
1. In patients with UA/NSTEMI undergoing PCI with clopidogrel
administration, it is reasonable to administer a GP IIb/IIIa
inhibitor (abciximab, eptifibatide, or tirofiban). (Level of Evidence:
B)§
§It is acceptable to administer the GP IIb/IIIa inhibitor before
performance of the diagnostic angiogram (“upstream treatment”)
or just before PCI (“in-lab treatment”).
See above (37).
2. In patients with STEMI undergoing PCI, it is reasonable to administer
abciximab as early as possible. (Level of Evidence: B)
Recommendation has been added for
consistency with the ACC/AHA Guidelines for
the Management of Patients With
ST-Elevation Myocardial Infarction (57,75–78).
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3. In patients undergoing elective PCI with stent placement, it is
reasonable to administer a GP IIb/IIIa inhibitor (abciximab,
eptifibatide, or tirofiban). (Level of Evidence: B)
Phrasing has been changed to reflect current terminology, especially in a
high-risk patient (79,80).
Class IIb
In patients with STEMI undergoing PCI, treatment with eptifibatide
or tirofiban may be considered. (Level of Evidence: C)
Recommendation has been added for consistency with the ACC/AHA
Guidelines for the Management of Patients With ST-Elevation
Myocardial Infarction.
6.2.3. Antithrombotic Therapy
6.2.3.1 Unfractionated Heparin, Low-Molecular-Weight Heparin, and Bivalirudin
Class I
The recommendations in this
section appeared in table
format in the 2001 guideline
(see 2001 Table). The
phrasing has been changed
to reflect current terminology
and to be consistent with
new evidence and/or
1. Unfractionated heparin should be administered to patients
undergoing PCI. (Level of Evidence: C)
Phrasing has been changed to reflect current terminology.
2. For patients with heparin-induced thrombocytopenia, it is
recommended that bivalirudin or argatroban be used to
replace heparin. (Level of Evidence: B)
Bivalirudin and argatroban are established therapies in place of
heparin among patients with heparin-induced thrombocytopenia (81,
82).
recommendations in the
ACC/AHA Guidelines for the
Management of Patients
With ST-Elevation Myocardial
Infarction and the ACC/AHA
2002 Guideline Update for
the Management of
Patients With Unstable
Angina/Non–ST-
Elevation Myocardial
Infarction.
Class IIa Class IIa
None 1. It is reasonable to use bivalirudin as an alternative to
unfractionated heparin and glycoprotein IIb/IIIa antagonists in
low-risk patients undergoing elective PCI. (Level of Evidence: B)
New recommendation is based on data from a clinical trial (REPLACE-2)
indicating bivalirudin is an acceptable alternative to heparin and GP IIb/IIIa
antagonists in low-risk patients undergoing PCI (83).
2. Low-molecular-weight heparin is a reasonable alternative
to unfractionated heparin in patients with UA/NSTEMI
undergoing PCI. (Level of Evidence: B)
Recommendation from the ACC/AHA 2002 Guideline Update for the
Management of Patients With Unstable Angina and Non–ST-Segment
Myocardial Infarction has been approved by this Writing Committee and
included in these guidelines for consistency.
Class IIb Class IIb
None Low-molecular-weight heparin may be considered as an
alternative to unfractionated heparin in patients with STEMI
undergoing PCI. (Level of Evidence: B)
Recommendation from the ACC/AHA Guidelines for the Management of
Patients With ST-Elevation Myocardial Infarction has been approved by this
Writing Committee and included in these guidelines for consistency.
6.3.4. Left Main CAD
Class IIa
None
Class IIa
It is reasonable that patients undergoing PCI to unprotected
left main coronary obstructions be followed up with coronary
angiography between 2 and 6 months after PCI. (Level of
Evidence: C)
Patients undergoing PCI to an unprotected left main coronary artery are at
higher risk for adverse events and should be monitored carefully. On the
basis of experience and opinion in the available reports, the Writing
Committee recommends angiography be performed between 2 and 6
months after PCI.
7.3.3. Management Strategies for Restenosis After PTCA
Class IIa Class IIa
None It is reasonable to consider that patients who develop
restenosis after PTCA or PTCA with atheroablative devices are
candidates for repeat coronary intervention with intracoronary
stents if anatomic factors are appropriate. (Level of Evidence: B)
This new recommendation reflects data indicating a significant
reduction in target-lesion revascularization and restenosis for patients
undergoing bare-metal stent placement compared with PTCA for
restenosis after PTCA (84).
7.3.5. Drug-Eluting Stents
Class I
None
Class I
A drug-eluting stent should be considered as an alternative
to the bare-metal stent in subsets of patients in whom trial
data suggest efficacy. (Level of Evidence: A)
New recommendation since the 2001 ACC/AHA Guidelines for Percutaneous
Coronary Intervention. Evidence continues to accumulate that supports the
use of drug-eluting stents (DES) versus bare-metal stents in certain subsets
in which DES results and outcomes are better (70, 71, 85–97).
Class IIb
None
Class IIb
A drug-eluting stent may be considered for use in anatomic
settings in which the usefulness, effectiveness, and safety have not
been fully documented in published trials. (Level of Evidence: C)
The data that a DES can improve clinical outcomes for PCI are generally
strong. However, DESs have not undergone evaluation for use in all clinical
situations and anatomic settings.
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Appendix. Abbreviations
CABG coronary artery bypass graft surgery
CAD coronary artery disease
CK creatine kinase
DES drug-eluting stent
ECG electrocardiogram
GP glycoprotein
HF heart failure
IVUS intravascular ultrasound
LAD left anterior descending artery
LBBB left bundle-branch block
LV left ventricular
MB cardiac muscle isoenzyme of
creatine kinase
MI myocardial infarction
MR mitral regurgitation
NSTEMI non–ST-elevation myocardial
infarction
PCI percutaneous coronary intervention
STEMI ST-elevation myocardial infarction
UA unstable angina
2001 TABLE. Recommendations for Pharmacological Management of Patients
Undergoing PCI—For Comparison Purposes Only (Deleted From 2005 Guideline)
Clinical Status
Transmural Myocardial Infarction
Drugs
Class I
Angina
Class II–IV
Angina, Unstable
Angina, NSTEMI
Acute
Phase MI
After
Thrombolysis
Hospital
Management
Phase
Aspirin I* I I I I
Ticlopidine, I‡ I I I I§
Clopidogrel†
Warfarin III III III II I¶
GP blockers# II I II I III
Abciximab
Tirofiban
Eptifibatide
Unfractionated heparin** I I I II III††
Note: This table has been deleted from the 2005 PCI Guideline Update. The recommendations
in this table were updated or deleted, as determined by the writing committee, and included
in the 2005 PCI Guideline Update in the recommendation list.
*Roman numerals indicate ACC/AHA class indication I, II, or III.
†In conjunction with stenting.
‡To be given 24–48 h before planned stenting, if possible.
§For 2 to 4 weeks after stent placement.
¶For patients without atrial fibrillation or other pre-existing clinical indications.
For patients with anterior myocardial wall motion abnormalities or LV thrombus.
#Every indication may not apply to all individual agents.
**Low-molecular-weight heparin is under investigation to replace unfractionated heparin.
††Other noncoronary thrombotic complications (eg, thrombophlebitis).
2001 Recommendation 2005 New or Revised Recommendation Comments
7.3.6.2 Drug-Eluting Stents for the Management of In-Stent Restenosis
Class IIa
None
Class IIa
It is reasonable to perform repeat PCI for in-stent restenosis
with a DES or a new DES for patients who develop in-stent
restenosis if anatomic factors are appropriate. (Level of
Evidence: B)
This is a new recommendation. Clinical trials comparing
sirolimus and paclitaxel DESs with PTCA for in-stent
restenosis demonstrate improved outcomes for the
DESs (97–101).
7.3.6.3. Radiation for Restenosis
Class IIa
None
Class IIa
Brachytherapy can be useful as a safe and effective treatment
for in-stent restenosis. (Level of Evidence: A)
This is a new recommendation since the 2001
ACC/AHA Guidelines for Percutaneous Coronary
Intervention based on evidence supporting the efficacy
of brachytherapy in the treatment of in-stent restenosis
(102–109).
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